NUVL
Nuvalent, Inc.
NASDAQ · Healthcare · Biotechnology · US
$123.96
+0.00%Latest reported
- Last report date
- May 7, 2026
- EPS actual
- -$1.39
- EPS estimate
- -$1.35
- Revenue actual
- —
- Revenue estimate
- $486.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -8.0%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $124
- PT range
- $124 – $124
- Analysts
- 11
0 Buy11 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Aug 6, 2026